File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000031997

Kabergovet 50 microgram/ml oral solution for dogs and cats.

Ima dovoljenje za promet

- Cabergoline

Informacije o zdravilu

Ime zdravila:
Kabergovet 50 microgram/ml oral solution for dogs and cats.

Učinkovina:
Na voljo samo v English

Ciljne živalske vrste:
Na voljo samo v Bulgarian Spanish Czech Danish German Estonian Greek English French Italian Latvian Lithuanian Hungarian Dutch Romanian Finnish Swedish Icelandic Norwegian
Na voljo samo v Bulgarian Spanish Czech Danish German Estonian Greek English French Italian Latvian Lithuanian Hungarian Dutch Romanian Finnish Swedish Icelandic Norwegian

Pot uporabe:
Peroralna uporaba

Podatki o zdravilu

Učinkovina / Jakost:
Na voljo samo v English

50.00 microgram(s) / 1.00 millilitre(s)

Farmacevtska oblika:
Peroralna tekočina

Anatomsko-terapevtsko-kemična veterinarska oznaka klasifikacija zdravil, ki se uporabljajo v veterini (ATCvet):
QG02CB03

Pravni status za dobavo/izdajo zdravila:
Zdravilo, ki se izdaja na veterinarski recept

Status dovoljenja za promet z zdravilom:
Valid

Ima dovoljenje za promet v:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo v:
Bulgaria

Opis ovojnine zdravila:
Na voljo samo v English
Na voljo samo v English

Dodatne informacije

Vrsta dovoljenja:
Na voljo samo v English French Croatian Italian Latvian Finnish Swedish Icelandic Norwegian

Pravna podlaga za izdajo dovoljenja za promet z zdravilom:
Na voljo samo v English Italian Latvian Norwegian

Imetnik dovoljenja za promet z zdravilom:
Vet-Agro Multi-Trade Company Sp. z o.o.

Datum dovoljenja za promet z zdravilom:
8/12/2020

Proizvodna mesta, odgovorna za sproščanje serij:
Przedsiebiorstwo Wielobranzowe Vet-Agro Sp. z o.o.

Pristojni organ:
Bulgarian Food Safety Authority

Številka dovoljenja za promet z zdravilom:
0022-3026

Datum spremembe statusa dovoljenja za promet:
8/12/2020

Referenčna država članica:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Številka postopka:
NL/V/0312/001

Zadevne države članice:
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Latvian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian
Na voljo samo v Spanish Czech German Estonian English French Croatian Italian Dutch Portuguese Slovak Swedish Icelandic Norwegian

---

Za poročila o domnevnih neželenih učinkih zdravil za uporabo v veterinaski medicini obiščite stran: www.adrreports.eu/vet

Dokumenti

Povzetek glavnih značilnosti zdravila

Ta dokument ne obstaja v tem jeziku (slovenščina). Lahko ga najdete spodaj v drugem jeziku.